Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel

Sir,

Nail psoriasis poses a therapeutic challenge. We report a 48-year-old Chinese man, with chronic plaque psoriasis and psoriatic arthropathy, who was seen at the National Skin Centre in Singapore. He was troubled by significant nail involvement despite methotrexate therapy and had a high baseline nail psoriasis severity index score of 62 [Figure 1a and b].[1] His past medical history included diabetes mellitus, hypertension, hyperlipidemia and gout. His cutaneous psoriasis had remained stable with a body surface area of 5%. He was receiving oral methotrexate 10 mg weekly for psoriatic arthropathy from his rheumatologist.

Topical calcipotriol 50 mcg/g with betamethasone dipropionate 0.5 mg/g combination gel once daily was applied to the proximal nail fold and distal nail bed. Shortly thereafter, his methotrexate was abruptly discontinued for 6 weeks due to a shortage of the medication. Consequently, he experienced a flare of his cutaneous psoriasis.

Despite being off methotrexate for 6 weeks, his nail psoriasis improved on treatment with calcipotriol with betamethasone dipropionate gel. There was reduction of pitting, yellowish discoloration, onycholysis and subungual hyperkeratosis. The nail psoriasis severity index decreased to 37 score after 6 weeks of application of the gel [Figure 2a and b]. Both nail matrix and nail bed disease showed marked improvement with scores decreasing from 38 to 18 and 24 to 19, respectively. The results were sustained when methotrexate was resumed for 11 weeks and calcipotriol with betamethasone dipropionate gel was used for a total of 22 weeks. At week 22, his final nail psoriasis severity index score was 31.

In patients, who have uncomplicated nail psoriasis with absent or mild cutaneous psoriasis, the first line of treatment is topical therapy. However, the topical treatment of nail psoriasis remains challenging for some reasons.[2] First, the nail plate presents a formidable barrier that limits the penetration of topical drugs to target sites in the nail bed and matrix. Second, poor adherence to topical treatment is a common as early nail disease is frequently asymptomatic and clinical improvement is slow. Third, there is a relative dearth of quality clinical evidence on the efficacy of various topical therapies for nail psoriasis.

Currently, the most widely used topical agents for the treatment of nail psoriasis are corticosteroids and vitamin D₃ analogs while intralesional injection of corticosteroids may be considered for patients with limited nail psoriasis. In an open-label study, a nightly regimen of calcipotriol cream on weekdays and clobetasol propionate cream on weekends for 6 months reduced subungual hyperkeratosis by
has been used anecdotally for treating nail psoriasis. In our patient, nail psoriasis responded well to calcipotriol with betamethasone dipropionate gel applied once daily with nail psoriasis severity index score reducing by 50% from 62 to 31 in 6 months. The treatment was well tolerated, and there was no evidence of any adverse effects such as steroid atrophy at the time of his last review. This two-compound formulation integrates the anti-inflammatory properties of a potent corticosteroid with the immunomodulatory effects of a vitamin D₃ analog. As a gel, it is more cosmetically elegant than an ointment and allows superior access to the nail bed when applied to the nail folds and hyponychium in onycholytic nails. The once-daily regimen confers the advantage of better treatment adherence which is important as topical treatment needs to be prolonged for several months to achieve optimal clinical response.

We were unable to find any previous reports showing therapeutic efficacy of calcipotriol with betamethasone dipropionate gel in the treatment of nail psoriasis. Our case suggests that this treatment may be considered a
Letters to the Editor

useful addition to the armamentarium of topical drugs for treating nail psoriasis.

Financial support and sponsorship
Nil.

Conflicts of interest
Dr. Eugene Sern-Ting Tan has received sponsorship for overseas meetings by AbbVie, Janssen Pharmaceuticals and LEO Pharma. Dr. Hazel Hwee-Boon Oon has received honoraria, grants and acted as a speaker and/or investigator for AbbVie, Galderma, Janssen Pharmaceuticals, LEO Pharma, Novartis and Pfizer.

Eugene Sern-Ting Tan, Hazel Hwee-Boon Oon
National Skin Centre, Singapore

Address for correspondence: Dr. Eugene Sern-Ting Tan, National Skin Centre, 1 Mandalay Road, 308205 Singapore. E-mail: dreugenetan@gmail.com

REFERENCES
1. Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
2. Tan ES, Chong WS, Tey HL. Nail psoriasis: A review. Am J Clin Dermatol 2012;13:375-88.
3. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002;82:140.
4. Tosti A, Piraccini BM, Cameli N, Kokely E, Plozzer C, Cannata GE, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998;139:655-9.
5. Rigopoulos D, Gregoriou S, Daniel III CR, Belyayeva H, Larios G, Verra P, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009;218:338-41.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online

How to cite this article: Tan ES, Oon HH. Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel. Indian J Dermatol Venereol Leprol 2016;82:345-7.

Received: March, 2015. Accepted: November, 2015.